Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
|Articles|March 13, 2017
Benchtop Nutsche Filter Dryer Improves Laboratory Process Development
PSL’s GFD benchtop nutsche filter dryer combines filtration, solids isolation, cake washing, and vacuum drying in one step.
Powder Systems Limited (PSL)’s next generation of its GFD benchtop nutsche filter dryer overcomes challenges with commonly used methods of Buchner filtration and oven drying. The dryer efficiently performs laboratory process development, combining filtration, solids isolation, cake washing, and vacuum drying all in one step. The final product is also fully recovered through a unique removable filtration basket.
With new features such as data logging, accurate control of the agitator speed and recipe input, the GFD can be autonomous and run processes without human intervention. Process data can be saved and exported for further analysis and repeatability. Now more compact and providing enhanced ergonomics, the new GFD can be integrated in fume hoods while maintaining good process visibility and reduced product exposure. Lab filtration and drying studies can be performed with the GFD plug-and-play system, available with full vacuum and heating ancillaries’ packages.
Source: PSL
Related to this article
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
2
Why Impurity Deficiencies Keep Repeating: AAPS PharmSci 360 2026
3
AAPS PharmSci 360: How USP Is Tackling the Novel Excipient Roadblock
4
Why Drug Shortages Average 5+ Years: PharmTech Explained
5